United States Cardiac Biomarkers Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global cardiac biomarkers market reached US$ 19.83 Billion with a rise of US$ 22.25 Billion in 2024 and is expected to reach US$ 67.53 Billion by 2033, growing at a CAGR of 13.22% during the forecast period 2025-2033.

Key Development:

United States: Recent Industry Developments

✅ In September 2025, BridgeBio Pharma announced that its heart-disease drug, Attruby, reduced the risk of cardiovascular death by 49% in an exploratory study. The drug, approved in late 2024 for treating cardiomyopathy caused by transthyretin amyloidosis, showed rapid benefits-improving outcomes within a month of treatment.

Japan: Recent Industry Developments

✅ In September 2025, Otsuka Pharmaceutical's Diagnostic Division inaugurated a new laboratory in Tokyo, focusing on biomarker and digital biomarker research to strengthen connections with users and enhance diagnostic capabilities.

✅ In June 2025, Cardio Diagnostics secured a Japanese patent for its AI-driven cardiovascular disease detection technology. The patent protects novel methods and compositions enabling the detection of cardiovascular disease risk and presence using epigenetic and genetic biomarkers interpreted through advanced machine learning algorithms.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cardiac-biomarkers-market?sb

Recent Mergers and Acquisitions:

United States: Recent M&A Activity in Cardiac Biomarkers

✅ In July 2025, Quanterix Corporation completed its acquisition of Akoya Biosciences, creating a leading platform capable of measuring biomarkers across both blood and tissue. This integration enhances Quanterix's capabilities in early disease detection, particularly in neurology, oncology, and immunology markets.

✅ In July 2025, Boston Scientific announced the acquisition of SoniVie Ltd., a company specializing in ultrasound-based renal denervation technology. This acquisition expands Boston Scientific's interventional cardiology therapies offerings, reflecting a growing focus on innovative cardiovascular solutions.

✅ In August 2024, VION Biosciences, a U.S.-based life sciences platform, acquired Ansh Labs for an undisclosed amount. This strategic move strengthens VION's presence in the diagnostic sector, integrating advanced technologies and expanding its product offerings in immunoassay development.

Japan: Recent M&A Activity in Cardiac Biomarkers

✅ In March 2025, Boston Scientific's acquisition of SoniVie Ltd. also impacted the Japanese market, enhancing the company's interventional cardiology offerings in the region. This move underscores the global expansion of advanced cardiac technologies.

✅ In June 2025, Cardio Diagnostics secured a Japanese patent for its AI-driven cardiovascular disease detection technology. While not an acquisition, this strategic development positions Cardio Diagnostics for potential partnerships or acquisitions in the Japanese market, leveraging its innovative approach to heart disease prevention.

Key Players:

=> Roche Diagnostics Limited, Abbott, Siemens Healthineers AG, Thermo Fisher Scientific Inc., AdvaCare Pharma, Novus Biologicals, Fine Biotech Co., Ltd., Labome, Vitrosens Biyoteknoloji, and Real-Gene Labs, among others.

Growth Forecast Projected:

The Global Cardiac Biomarkers Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Cardiac Biomarkers Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cardiac-biomarkers-market

Key Segments:

➥ By Cardiac Biomarker Tests: Troponin, Creatine kinase, Myoglobin, Galectin-3, Others

➥ By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Angina, Others

➥ By Testing Location: Laboratory Testing, Point of Care Testing

Regional Analysis for Cardiac Biomarkers Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Cardiac Biomarkers producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Cardiac Biomarkers revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cardiac-biomarkers-market?sb

FAQ

What is the current size of the Cardiac Biomarkers Market?

A: In 2024, the Cardiac Biomarkers Market was valued at US$ 22.25 Billion in 2024, reflecting its strong industry presence.

Q2: How large is the Cardiac Biomarkers Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Cardiac Biomarkers Market will grow to around US$ 67.53 Billion by 2033, demonstrating significant expansion.

Q3: What is the growth rate of the Cardiac Biomarkers Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 13.22% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.